<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281459</url>
  </required_header>
  <id_info>
    <org_study_id>SCT 4/7</org_study_id>
    <nct_id>NCT04281459</nct_id>
  </id_info>
  <brief_title>Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction</brief_title>
  <official_title>Short Cycle Therapy in ART Regimens Containing Rilpivirine: Assessment of Patients' Satisfaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this study the investigators propose to evaluate the satisfaction of the patients
      receiving antiretroviral treatment for HIV infection with standard everyday scheme, compared
      to patients receiving the same treatment with short-cycles of 4 days a week.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to evaluate the impact of SCT on the quality of life of HIV infected
      adults by administering HIV Treatment Satisfaction Questionnaires (HIV-TSQs) to patients
      receiving SCT for at least 48 weeks and by comparing their answers to those of patients
      receiving standard 7-days-a-week ART with comparable therapeutic regimens.

      This is an interventional study performed at the HIV outpatients clinics of the Infectious
      and Tropical Diseases department in Azienda Ospedaliera Universitaria Integrata of Verona
      (Italy).

      During standard visits and after collecting their informed consent, the investigators will
      administer HIV-TSQs to 30 patients receiving 4-days-a-week of rilpivirine-containing regimens
      (either rilpivrine/emtricitabine/tenofovir alafenamide or rilpivirine + lamivudine/abacavir)
      and to 30 patients receiving the same regimens but 7-days-a-week.

      For the first group, the investigators will consider patients who have switched to a SCT at
      least 48 weeks before administration of the questionnaire, and data on their
      viro-immunological status (HIV-RNA, CD4+ cells count and CD4+/CD8+ ratio) after the switch to
      SCT will be retrospectively collected as well.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patients' satisfaction with their treatment: HIVTSQs</measure>
    <time_frame>immediately after outpatient visit</time_frame>
    <description>The patients satisfaction will be assessed using HIVTSQs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Virological suppression in the SCT group</measure>
    <time_frame>48 weeks before enrollment</time_frame>
    <description>all the Viral Load (copies/ml) determinations in the 48 weeks before enrollment will be registered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ cells count and CD4+/CD8+ ratio in the SCT group</measure>
    <time_frame>48 weeks before enrollment</time_frame>
    <description>all the CD4+ cells and CD4+/CD8+ determinations in the 48 weeks before enrollment will be registered</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>SCT 4/7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving 3-drug antiretroviral therapy containing rilpivirine with short cycle scheme of 4 consecutive days on and 3 days off treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving 3-drug antiretroviral therapy containing rilpivirine with standard scheme of 7 days per week of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HIV Treatment Satisfaction Questionnaire status</intervention_name>
    <description>Administration of pseudoanonymous HIV-TSQs (translated into Italian) to all included patients.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>SCT 4/7</arm_group_label>
    <other_name>HIV-TSQs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 chronic infection;

          -  therapy with three-drugs and standard dosage ART containing rilpivirine: either
             rilpivirine/emtricitabine/tenofovir alafenamide (Odefsey) or
             rilpivirine/lamivudine/abacavir;

          -  virological suppression (VL&lt;50 copies/ml) for at least 12 months before switching to
             SCT. One viral blip with VL&lt;200 copies/ml, followed by a second deterrmination after
             30 days &lt;20 copies/ml is admitted;

          -  CD4+ cells count &gt;200/mmc;

          -  no evidence or history of viral resistances against NNRTIs, tenofovir, emtricitabine,
             abacavir and lamivudine; no history of previous failures with their ART regimens;

          -  ability to provide written informed consent.

        Exclusion Criteria:

          -  evidence or history of viral resistances against NNRTIs, tenofovir, emtricitabine,
             abacavir and lamivudine; history of previous failures with their ART regimen;

          -  diagnosis of any opportunistic infection in the 2 weeks before enrollment;

          -  for women, ongoing pregnancy and lactation;

          -  history of HBV infection (positive anti-HBc antibodies, with negative anti-HBs
             antibodies);

          -  therapy with experimental drugs/chemotherapy/radiotherapy in the 12 weeks before
             enrolment;

          -  current abuse of drugs or alcohol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Massimiliano Lanzafame, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AOUI Verona - UOC Malattie Infettive e Tropicali</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dora Luise, MD</last_name>
    <phone>(+39) 3409631535</phone>
    <email>luise.dora@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Massimiliano Lanzafame, MD</last_name>
    <phone>(+39) 045 812 8243</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AOUI Verona - UOC Malattie Infettive e Tropicali c/o Policlinico GB Rossi</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Segreteria</last_name>
      <phone>(+39) 045 8128243</phone>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Cohen CJ, Colson AE, Sheble-Hall AG, McLaughlin KA, Morse GD. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study. HIV Clin Trials. 2007 Jan-Feb;8(1):19-23.</citation>
    <PMID>17434845</PMID>
  </reference>
  <reference>
    <citation>Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT Jr, Mugyenyi P, Fauci AS, Quinn TC, Dybul MR. A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One. 2010 Apr 22;5(4):e10307. doi: 10.1371/journal.pone.0010307.</citation>
    <PMID>20442758</PMID>
  </reference>
  <reference>
    <citation>BREATHER (PENTA 16) Trial Group. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV. 2016 Sep;3(9):e421-e430. doi: 10.1016/S2352-3018(16)30054-6. Epub 2016 Jun 20.</citation>
    <PMID>27562743</PMID>
  </reference>
  <reference>
    <citation>Rudy BJ, Sleasman J, Kapogiannis B, Wilson CM, Bethel J, Serchuck L, Ahmad S, Cunningham CK; Adolescent Trials Network for HIV/AIDS Interventions. Short-cycle therapy in adolescents after continuous therapy with established viral suppression: the impact on viral load suppression. AIDS Res Hum Retroviruses. 2009 Jun;25(6):555-61. doi: 10.1089/aid.2008.0203.</citation>
    <PMID>19534628</PMID>
  </reference>
  <reference>
    <citation>Leibowitch J, Mathez D, de Truchis P, Ledu D, Melchior JC, Carcelain G, Izopet J, Perronne C, David JR. Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. FASEB J. 2015 Jun;29(6):2223-34. doi: 10.1096/fj.14-260315. Epub 2015 Apr 1.</citation>
    <PMID>25833895</PMID>
  </reference>
  <reference>
    <citation>de Truchis P, Assoumou L, Landman R, Mathez D, Le Dû D, Bellet J, Amat K, Katlama C, Gras G, Bouchaud O, Duracinsky M, Abe E, Alvarez JC, Izopet J, Saillard J, Melchior JC, Leibowitch J, Costagliola D, Girard PM, Perronne C; ANRS 162-4D Study Group. Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. J Antimicrob Chemother. 2018 Mar 1;73(3):738-747. doi: 10.1093/jac/dkx434.</citation>
    <PMID>29186458</PMID>
  </reference>
  <reference>
    <citation>Woodcock A, Bradley C. Validation of the revised 10-item HIV Treatment Satisfaction Questionnaire status version and new change version. Value Health. 2006 Sep-Oct;9(5):320-33.</citation>
    <PMID>16961550</PMID>
  </reference>
  <reference>
    <citation>Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients (QUATUOR). Identification number: NCT03256422</citation>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>February 21, 2020</last_update_submitted>
  <last_update_submitted_qc>February 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Short-cycle therapy</keyword>
  <keyword>SCT</keyword>
  <keyword>rilpivirine</keyword>
  <keyword>HIVTSQs</keyword>
  <keyword>patients' satisfaction</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We will consider sharing IPD upon request by other researchers.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>From start of recruitment onwards</ipd_time_frame>
    <ipd_access_criteria>by email to the main investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

